{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:48:34Z","timestamp":1788104914652,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The majority of breast cancer patients have tumors expressing estrogen receptor \u03b1 (ER) and are treated with adjuvant endocrine therapy. However, nearly one-third relapse, most with retained ER expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study investigated patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer. Patients with ER-positive relapses within five years of ongoing endocrine therapy were defined as endocrine-resistant (<jats:italic>N<\/jats:italic>\u2009=\u200969). Patients with no disease progression after 10\u00a0years were defined as endocrine-sensitive (<jats:italic>N<\/jats:italic>\u2009=\u200977). RNA was extracted from archived tumor blocks, followed by gene expression analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Significant differences were observed with higher tumor grades, intrinsic subtype risk scores, and upregulated cell-cycle gene sets in resistant compared to sensitive patients\u2019 primary tumors. Metabolism-associated gene sets were upregulated, and estrogen-response gene sets downregulated in resistant patients' relapse compared to primary tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study highlights gene sets associated with endocrine resistance and identifies transcriptomic and clinicopathological profiles that may serve as potential prognostic markers for therapy response.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14826-1","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T07:35:08Z","timestamp":1760340908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Transcriptomic profiles of endocrine-resistant breast cancer"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5300-640X","authenticated-orcid":false,"given":"Caroline","family":"Schagerholm Stanev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil G.","family":"Sifakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linnea","family":"Hases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-8527","authenticated-orcid":false,"given":"Johan","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"14826_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"14826_CR2","doi-asserted-by":"crossref","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021; 32: 1216\u20131235.","DOI":"10.1016\/j.annonc.2021.06.023"},{"key":"14826_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382.","journal-title":"Ann Oncol"},{"key":"14826_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"14826_CR5","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T S\u00f8rlie","year":"2001","unstructured":"S\u00f8rlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14826_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"CGA Network","year":"2012","unstructured":"Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"issue":"Suppl 2","key":"14826_CR7","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","volume":"24","author":"A Prat","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, Galv\u00e1n P, Fern\u00e1ndez A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26-35.","journal-title":"Breast"},{"key":"14826_CR8","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726\u201334.","journal-title":"J Clin Oncol"},{"key":"14826_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111\u201321.","journal-title":"N Engl J Med"},{"key":"14826_CR10","unstructured":"Confederation of Regional Cancer Centres in Sweden. National Clinical Cancer Care Guidelines Breast Cancer. 2024.\u00a0https:\/\/kunskapsbanken.cancercentrum.se\/globalassets\/cancerdiagnoser\/brost\/vardprogram\/nationellt-vardprogram-brostcancer.pdf (Accessed 24 Oct 2024)."},{"key":"14826_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288\u2013300.","journal-title":"JAMA"},{"key":"14826_CR12","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341\u20131352.","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"14826_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","volume":"126","author":"SK Herzog","year":"2022","unstructured":"Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126:174\u201386.","journal-title":"Br J Cancer"},{"key":"14826_CR14","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022; 23: 382\u2013392."},{"key":"14826_CR15","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388:2058\u201370.","journal-title":"N Engl J Med"},{"key":"14826_CR16","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard F-C, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246\u201356.","journal-title":"J Clin Oncol"},{"key":"14826_CR17","doi-asserted-by":"crossref","unstructured":"Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A. Targeted therapies, sequencing strategies, and beyond in metastatic hormone receptor-positive breast cancer: ASCO guideline clinical insights. JCO Oncol Pract 2024; : OP2400547.","DOI":"10.1200\/OP-24-00547"},{"key":"14826_CR18","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.3747\/co.25.3752","volume":"25","author":"A AlFakeeh","year":"2018","unstructured":"AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol. 2018;25:S18\u201327.","journal-title":"Curr Oncol"},{"key":"14826_CR19","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771\u2013784.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"14826_CR20","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836\u201346.","journal-title":"N Engl J Med"},{"key":"14826_CR21","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687\u20131717.","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"14826_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s11033-021-06863-3","volume":"49","author":"F Miranda","year":"2022","unstructured":"Miranda F, Prazeres H, Mendes F, Martins D, Schmitt F. Resistance to endocrine therapy in HR + and\/or HER2 + breast cancer: the most promising predictive biomarkers. Mol Biol Rep. 2022;49:717\u201333.","journal-title":"Mol Biol Rep"},{"issue":"Pt 3","key":"14826_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","volume":"418","author":"R Clarke","year":"2015","unstructured":"Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer\u2013An overview and update. Mol Cell Endocrinol. 2015;418(Pt 3):220\u201334.","journal-title":"Mol Cell Endocrinol"},{"key":"14826_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111322","volume":"532","author":"F Rasha","year":"2021","unstructured":"Rasha F, Sharma M, Pruitt K. Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol. 2021;532: 111322.","journal-title":"Mol Cell Endocrinol"},{"key":"14826_CR25","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125:3714\u201328.","journal-title":"Cancer"},{"key":"14826_CR26","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","volume":"99","author":"O Saatci","year":"2021","unstructured":"Saatci O, Huynh-Dam K-T, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med. 2021;99:1691\u2013710.","journal-title":"J Mol Med"},{"key":"14826_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3389\/fendo.2019.00573","volume":"10","author":"MM Haque","year":"2019","unstructured":"Haque MM, Desai KV. Pathways to Endocrine Therapy Resistance in Breast Cancer. Front Endocrinol. 2019;10:573.","journal-title":"Front Endocrinol"},{"key":"14826_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020;37:496\u2013513.","journal-title":"Cancer Cell"},{"key":"14826_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/jnci\/djy088","volume":"110","author":"W Sauerbrei","year":"2018","unstructured":"Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An abridged explanation and elaboration. J Natl Cancer Inst. 2018;110:803\u201311.","journal-title":"J Natl Cancer Inst"},{"key":"14826_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cncy.20147","volume":"119","author":"HM Moore","year":"2011","unstructured":"Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119:92\u2013101.","journal-title":"Cancer Cytopathol"},{"key":"14826_CR31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645\u201359.","journal-title":"Ann Oncol"},{"key":"14826_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, M\u00fcller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105\u201313.","journal-title":"J Clin Oncol"},{"key":"14826_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259\u201371.","journal-title":"Ann Oncol"},{"key":"14826_CR34","unstructured":"BEA core facility. Bioinformatics and Expression Analysis. http:\/\/www.bea.ki.se\/ (accessed 5 Mar2023)."},{"key":"14826_CR35","unstructured":"Thermo Fisher Scientific Inc. Transcriptome Analysis Console (TAC) v4.0.3 User Guide. Affymetrix Inc., 2022https:\/\/www.thermofisher.com\/content\/dam\/LifeTech\/Documents\/PDFs\/TAC_v4.0.3_User_Guide.pdf (accessed 24 Oct2024)."},{"key":"14826_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373.","journal-title":"Nat Genet"},{"key":"14826_CR37","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14826_CR38","doi-asserted-by":"crossref","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27: 1739\u20131740.","DOI":"10.1093\/bioinformatics\/btr260"},{"key":"14826_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"issue":"1","key":"14826_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28(1):27. https:\/\/doi.org\/10.1093\/nar\/28.1.27.","journal-title":"Nucleic Acids Res"},{"key":"14826_CR41","doi-asserted-by":"publisher","unstructured":"Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52(D1):D672\u20138. https:\/\/doi.org\/10.1093\/nar\/gkad1025.","DOI":"10.1093\/nar\/gkad1025"},{"key":"14826_CR42","unstructured":"The Broad Institute. GSEA User Guide. GSEA. 2004\u20132024.\u00a0http:\/\/www.gsea-msigdb.org\/gsea\/doc\/GSEAUserGuideFrame.html?_Interpreting_GSEA_Results (Accessed 24 Oct 2024)."},{"key":"14826_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346\u201352.","journal-title":"Nature"},{"key":"14826_CR44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","volume":"567","author":"OM Rueda","year":"2019","unstructured":"Rueda OM, Sammut S-J, Seoane JA, Chin S-F, Caswell-Jin JL, Callari M, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567:399\u2013404.","journal-title":"Nature"},{"key":"14826_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"14826_CR46","unstructured":"Bhuva D, Smyth G, Garnham A. msigdb: An ExperimentHub Package for the Molecular Signatures Database (MSigDB). R package version 1.14.0. 2024.\u00a0https:\/\/davislaboratory.github.io\/msigdb."},{"key":"14826_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13058-015-0520-4","volume":"17","author":"X Zhao","year":"2015","unstructured":"Zhao X, R\u00f8dland EA, Tibshirani R, Plevritis S. Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res. 2015;17:29.","journal-title":"Breast Cancer Res"},{"key":"14826_CR48","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160\u20137.","journal-title":"J Clin Oncol"},{"key":"14826_CR49","unstructured":"R Foundation for Statistical Computing, Vienna, Austria. R: A language and environment for statistical computing. https:\/\/www.R-project.org\/."},{"key":"14826_CR50","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-16-2092","volume":"23","author":"A Prat","year":"2017","unstructured":"Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, et al. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse. Clin Cancer Res. 2017;23:3035\u201344.","journal-title":"Clin Cancer Res"},{"key":"14826_CR51","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1158\/1078-0432.CCR-20-4102","volume":"27","author":"T Pascual","year":"2021","unstructured":"Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Pernas S, Gavila J, et al. Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor\u2013positive HER2-positive breast cancer treated with neoadjuvant anti\u2013HER2-based therapy. Clin Cancer Res. 2021;27:3116\u201325.","journal-title":"Clin Cancer Res"},{"key":"14826_CR52","unstructured":"Microsoft Corporation. Microsoft\u00ae Excel\u00ae for Microsoft 365 MSO. Available from: https:\/\/office.microsoft.com\/excel."},{"key":"14826_CR53","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol 2021; 39: 2720\u20132731.","DOI":"10.1200\/JCO.20.03613"},{"key":"14826_CR54","doi-asserted-by":"crossref","unstructured":"Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700\u20131712.","DOI":"10.1093\/annonc\/mdx308"},{"key":"14826_CR55","doi-asserted-by":"crossref","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn H-J et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736\u20131747.","DOI":"10.1093\/annonc\/mdr304"},{"key":"14826_CR56","doi-asserted-by":"crossref","unstructured":"Yu NY, Iftimi A, Yau C, Tobin NP, van \u2019t Veer L, Hoadley KA et al. Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in postmenopausal patients with luminal A or luminal B breast cancer. JAMA Oncol 2019; 5: 1304\u20131309.","DOI":"10.1001\/jamaoncol.2019.1856"},{"key":"14826_CR57","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00432-018-2644-2","volume":"144","author":"A Ignatov","year":"2018","unstructured":"Ignatov A, Eggemann H, Burger E, Ignatov T. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 2018;144:1347\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"key":"14826_CR58","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-13-1845","volume":"20","author":"M Filipits","year":"2014","unstructured":"Filipits M, Nielsen TO, Rudas M, Greil R, St\u00f6ger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20:1298\u2013305.","journal-title":"Clin Cancer Res"},{"key":"14826_CR59","doi-asserted-by":"publisher","unstructured":"Clusan L, Ferri\u00e8re F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci 2023; 24. https:\/\/doi.org\/10.3390\/ijms24076834.","DOI":"10.3390\/ijms24076834"},{"key":"14826_CR60","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00026.2006","volume":"87","author":"N Heldring","year":"2007","unstructured":"Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905\u201331.","journal-title":"Physiol Rev"},{"key":"14826_CR61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","volume":"116","author":"N Fuentes","year":"2019","unstructured":"Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135\u201370.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"Suppl 2","key":"14826_CR62","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","volume":"24","author":"A Nardone","year":"2015","unstructured":"Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. The changing role of ER in endocrine resistance. Breast. 2015;24(Suppl 2):S60\u20136.","journal-title":"Breast"},{"key":"14826_CR63","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ijc.24750","volume":"126","author":"SE Ghayad","year":"2010","unstructured":"Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K\/Akt signaling pathways. Int J Cancer. 2010;126:545\u201362.","journal-title":"Int J Cancer"},{"key":"14826_CR64","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"14826_CR65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25\u201335.","journal-title":"Lancet Oncol"},{"key":"14826_CR66","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2017.76.9331","volume":"36","author":"N Kornblum","year":"2018","unstructured":"Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol. 2018;36:1556\u201363.","journal-title":"J Clin Oncol"},{"key":"14826_CR67","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"14826_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12920-018-0449-4","volume":"12","author":"X Wang","year":"2019","unstructured":"Wang X, Sun Z, Zimmermann MT, Bugrim A, Kocher J-P. Predict drug sensitivity of cancer cells with pathway activity inference. BMC Med Genomics. 2019;12:15.","journal-title":"BMC Med Genomics"},{"key":"14826_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.599586","volume":"12","author":"EB Belachew","year":"2021","unstructured":"Belachew EB, Sewasew DT. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Front Endocrinol. 2021;12: 599586.","journal-title":"Front Endocrinol"},{"key":"14826_CR70","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10549-008-9897-4","volume":"112","author":"DME Harvell","year":"2008","unstructured":"Harvell DME, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, et al. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008;112:475\u201388.","journal-title":"Breast Cancer Res Treat"},{"key":"14826_CR71","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13045-018-0670-9","volume":"11","author":"X Liang","year":"2018","unstructured":"Liang X, Briaux A, Becette V, Benoist C, Boulai A, Chemlali W, et al. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). J Hematol Oncol. 2018;11:124.","journal-title":"J Hematol Oncol"},{"key":"14826_CR72","doi-asserted-by":"publisher","unstructured":"Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Matsuyama R et al. G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. Int J Mol Sci 2020; 21. https:\/\/doi.org\/10.3390\/ijms21082921.","DOI":"10.3390\/ijms21082921"},{"key":"14826_CR73","doi-asserted-by":"publisher","unstructured":"Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M et al. The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+\/HER2- Breast Cancer. Cells 2020; 9. https:\/\/doi.org\/10.3390\/cells9071643.","DOI":"10.3390\/cells9071643"},{"key":"14826_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12672-024-00875-8","volume":"15","author":"W-J Shen","year":"2024","unstructured":"Shen W-J, Zhang Y. RPN1 promotes the proliferation and invasion of breast cancer cells by activating the PI3K\/AKT\/mTOR signaling pathway. Discov Oncol. 2024;15:25.","journal-title":"Discov Oncol"},{"key":"14826_CR75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10549-021-06336-y","volume":"189","author":"M Althobiti","year":"2021","unstructured":"Althobiti M, El-Sharawy KA, Joseph C, Aleskandarany M, Toss MS, Green AR, et al. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. Breast Cancer Res Treat. 2021;189:621\u201330.","journal-title":"Breast Cancer Res Treat"},{"key":"14826_CR76","doi-asserted-by":"publisher","unstructured":"Oshi M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Endo I et al. Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer. Cancers 2020; 12. https:\/\/doi.org\/10.3390\/cancers12123557.","DOI":"10.3390\/cancers12123557"},{"key":"14826_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.865024","volume":"12","author":"T Takeshita","year":"2022","unstructured":"Takeshita T, Tokumaru Y, Oshi M, Wu R, Patel A, Tian W, et al. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. Front Oncol. 2022;12: 865024.","journal-title":"Front Oncol"},{"key":"14826_CR78","first-page":"2057","volume":"19","author":"I Elfaki","year":"2018","unstructured":"Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018;19:2057\u201370.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"14826_CR79","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/1055-9965.EPI-24-1617","volume":"34","author":"W Schroth","year":"2025","unstructured":"Schroth W, M\u00fcrdter TE, Schwab M. Unraveling the impact of drug metabolism on tamoxifen response in breast cancer. Cancer Epidemiol Biomarkers Prev. 2025;34(2):221\u20133.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"14826_CR80","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-020-00320-2","volume":"21","author":"G Bergers","year":"2021","unstructured":"Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21(3):162\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"14826_CR81","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","volume":"14","author":"J Reimand","year":"2019","unstructured":"Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA. Cytoscape and EnrichmentMap Nat Protoc. 2019;14(2):482\u2013517.","journal-title":"Cytoscape and EnrichmentMap Nat Protoc"},{"key":"14826_CR82","doi-asserted-by":"crossref","unstructured":"Bull C, Byrne RM, Fisher NC, Corry SM, Amirkhah R, Edwards J, et al. Dual gene set enrichment analysis (dualGSEA); an R function that enables more robust biological discovery and pre-clinical model alignment from transcriptomics data. Sci Rep 2024 4;14(1):30202.","DOI":"10.1038\/s41598-024-80534-8"},{"issue":"1","key":"14826_CR83","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1038\/s41467-023-40022-5","volume":"14","author":"R El-Botty","year":"2023","unstructured":"El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat Commun. 2023;14(1):4221.","journal-title":"Nat Commun"},{"key":"14826_CR84","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1038\/s41598-018-24781-6","volume":"8","author":"I Wimmer","year":"2018","unstructured":"Wimmer I, Tr\u00f6scher AR, Brunner F, Rubino SJ, Bien CG, Weiner HL, et al. Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples. Sci Rep. 2018;8:6351.","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"14826_CR85","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1\u20132):373-386.e10.","journal-title":"Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14826-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14826-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14826-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:04:16Z","timestamp":1760346256000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14826-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14826"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14826-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. The study was approved by the Regional Ethical Review Board in Stockholm (Regionala Etikpr\u00f6vningsn\u00e4mnden i Stockholm) and the Swedish Ethical Review Authority (Etikpr\u00f6vningsmyndigheten). Patients provided informed consent before surgery to store tissue samples in the Stockholm Medical Biobank for clinical and research purposes. No additional informed consent was required in accordance with the ethical approval in this non-interventional data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JH has obtained speaker\u2019s honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Pfizer, Eli Lilly, MSD, Sakura, and Gilead, and has received institutional research support from Cepheid, Novartis, Roche, MSD, and AstraZeneca. JH is a co-founder and shareholder of Stratipath AB, business related to this work. No patents related to this work. SR is employed by Stratipath AB and holds employee stock options, and has received speaker\u2019s honoraria from Novartis and Roche. CSS has received speaker\u2019s honoraria from Novartis. ES, LH, XC, and CW declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1556"}}